Navigation Links
KICVentures Unveils New Investment Opportunities in AxioMed® and NanoFUSE™ Biologics for 2019 at AAOS
Date:2/26/2019

KICVentures, a Boston-based private investment firm leading in healthcare technology, announced today new investment opportunities in two disruptive spine companies will be presented at American Academy of Orthopedic Surgeons (AAOS) in Las Vegas on March 12-16th.

“The spine industry is consolidating as evidenced by multiple acquisitions which creates a favorable opportunity for investors,” said Dr. Kingsley R. Chin. “Also favorable is the outlook that consolidation and market expansion will continue for the next 5 years as larger device players respond to growth pressures and to new innovations in the areas of motion preservation and biologics.”

KICVentures is seeking investment to prepare two disruptive spine companies, AxioMed and NanoFUSE Biologics LLC, for acquisition in the next 3-5 years.

The AxioMed Freedom™ Disc is a revolutionary cervical and lumbar spinal disc replacement that identically acts like the natural disc because of its patented viscoelastic material. The AxioMed disc has an exclusive 15-year license to the viscoelastic material, robust IP, in-house manufacturing, and manufacturing trade secrets. It is the first and only viscoelastic disc replacement to complete a USA, IDE lumbar clinical study.

The lumbar disc has over 5 years of clinical follow-up data and a USA release is expected in 2020 with the hopes of a lateral indication to compete against NuVasive’s lateral fusion. The AxioMed Freedom Cervical Disc, 3-level clinical trials are expected to begin in 2019 and will be the only clinical trial of a cervical viscoelastic disc with multi-level indications.

NanoFUSE Biologics is the only bioactive glass that is FDA-cleared to be combined with DBM. To replicate this one-of-a-kind orthobiologic, the competition would need a clinical IDE study, which gives NanoFUSE a 5-year competitive advantage to start. Bioactive glass has been clinically proven in orthopedics for over 30 years.

“The patented NanoFUSE manufacturing process produces an advanced bioactive glass with high efficacy demonstrated in animal studies,” states NanoFUSE President, Jake Lubinski. “We’re excited about the growing surgeon adoption of NanoFUSE, as it has been used by over 300 surgeons and implanted in over 1200 patients.”

To finance growth, KICVentures has opened a limited number of investment opportunities to qualified investors with a minimum investment of $25,000.

KICVentures will be represented by AxioMed, NanoFUSE and SpineFrontier at Booth #2273 at AAOS.

About KICVentures

KICVentures is a private investment company founded in 2005 by Harvard-trained Orthopedic Surgeon & Professor Dr. Kingsley R. Chin, who brings unique experience at the intersection of medicine, business and information technology. KICVentures is equipped with a strong advantage in identifying niche healthcare opportunities, and is headquartered in Boston, Mass.

About AxioMed

AxioMed was founded to advance the standard of care for patients with degenerative spine conditions by progressing spine technology beyond fusion and first-generation artificial discs. Led by an experienced surgeon team and utilizing patented viscoelastic polymer technology, AxioMed has developed the next generation of artificial discs. AxioMed completed its U.S. IDE for the Lumbar Disc with over five years of clinical follow-up.

About NanoFUSE Biologics

NanoFUSE is the synergistic blend of osteoinductive DBM combined with the osteostimulative properties of bioactive glass. NanoFUSE is the only FDA-cleared combination of DBM and bioactive glass and is indicated for use in all orthopedic surgery. NanoFUSE Biologics is a KICVentures portfolio company, and is distributed by SpineFrontier.

Read the full story at https://www.prweb.com/releases/kicventures_unveils_new_investment_opportunities_in_axiomed_and_nanofuse_biologics_for_2019_at_aaos/prweb16121831.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related medicine news :

1. KICVentures Announces Investment Opportunity to Prepare AxioMed and NanoFUSE Biologics for Acquisition
2. KICVentures Sees Recent $1B Acquisition in Spine as an Industry Shift Towards Big Companies Valuing Disc Replacement Technology.
3. KICVentures Gathers Successful Columbia Soccer Alumni to Give Back to Student Athletes
4. Ultimate Medical Academy Unveils Mascot – the Pumas – to Kick off the Healthcare School’s 25th Anniversary Year
5. Top General Dentist In Woodland Hills Unveils an Innovative and Affordable Method to Insert Dental Implants
6. Cantata Health Unveils Key Additions to EHR Software for Long-term Care Providers
7. DuPont Nutrition & Health Unveils New Research on Plant-Based Eating
8. My Cuistot Unveils New Parisian-Inspired, Chef-Cooked Healthy Meal Delivery Service
9. Yisrayl Hawkins Unveils Bible Prophecy Meanings Hidden for Thousands of Years
10. Top Chicago Plastic Surgeon Unveils Unique Minimal Incision Surgery
11. The Garland Company Unveils Redesigned, Customer-Centric Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2019)... ... September 17, 2019 , ... ... help extend the lives of some cancer patients? In companion presentations at the ... Roswell Park Comprehensive Cancer Center report new evidence that low-dose aspirin and other ...
(Date:9/17/2019)... ... September 17, 2019 , ... ... that he has been certified by the American Academy of Facial Esthetics (AAFE) ... correct a wide range of orofacial conditions such as tooth clenching and grinding, ...
(Date:9/17/2019)... (PRWEB) , ... September 17, 2019 , ... ... advocacy group BPAN Warriors , with the goal of providing resources to ... Beta-Propeller Protein-Associated Neurodegeneration (BPAN), a progressive disease causing abnormal iron deposits in the ...
(Date:9/17/2019)... ... September 17, 2019 , ... CORE Medical ... Dr. Yevgeniya (Jenny) Gartshteyn to their team of expert physicians. Dr. Gartshteyn completed ... the Clinical Appointment of Assistant Professor in Medicine for the Division of Hospitalist ...
(Date:9/14/2019)... ... September 13, 2019 , ... ... detection and treatment of infectious diseases at its annual Congress (WMIC) recently ... detection of residual HIV infected cell persistence and the development of pathogen-specific ...
Breaking Medicine News(10 mins):
(Date:9/17/2019)... ... 18, 2019 , ... Uniform Advantage (UA), a leader in the ... Breast Cancer programs and services. , This year, more than 271,000 Americans will be ... the month of October 2019, Uniform Advantage will donate $5 for every unique use ...
(Date:9/17/2019)... ... September 17, 2019 , ... Scientists writing ... therapeutic agents to stop the progressive destruction of joint cartilage in osteoarthritis are ... Miami-based hand and upper limb orthopedic surgeon Alejandro Badia, MD , founder ...
(Date:9/17/2019)... ... ... Drs. Nickelice Brand and Chris Williams restore smiles of Ocala, FL patients by ... are a nearly permanent, comfortable and efficient way for patients to replace their missing ... placed by highly trained professionals such as Drs. Brand and Williams, providing patients a ...
Breaking Medicine Technology: